FOXP2 silencing in breast cancer promoted cancer stem cells and tumor metastasis, while elevated miR-199a and reduced FOXP2 expression correlated with a significantly inferior outcome for patients [46]. This evidence concerns the gene FOXP2 and breast carcinoma.